Adjuvant Chemotherapy Folfox Combined with Concurrent Radiotherapy in Postsurgery Gastric Cancer Patient: Phase I Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-09000310

Enrollment

Unknown

Registered

2009-01-15

Start date

2009-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

Group 2:Oxaliplatin 65 mg/m2

Group 4:Oxaliplatin 85 mg/m2

Group 3:Oxaliplatin 75 mg/m2

Group 1:Oxaliplatin 75 mg/m2

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age from 18-75y; 2. Pathology is adenocarcinoma of gastric; 3. Post-surgery stage is T3-4, N0-3, M0; 4. Tumor was completely removed; 5. KPS >=70; 6. Patients did not receive any chemotherapy or radiotherapy in recent 6 months; or it is more than 4 weeks after chemotherapy before; 7. The results of blood tests are normal (HB>=12g/l, WBC>=4.0*10^9/l, PLT>=100*10^9/l, Crea, TB <=1.0 folders; ALT, AST<=2.5 folders); 8. be no more than 3 moths after surgery.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactation women; 2. Serious heart disease, uncontrolled Diabetic or psycologic disease; 3. The secondary tumor; 4. Seriously or uncontrolled infection; 5. Participant in another trial in the initial 4 weeks.

Design outcomes

Primary

Measure	Time frame
MTD (maximum tolerated dose);	—

Secondary

Measure	Time frame
DLT (Dose Limited Toxicity);	—

Countries

China

Contacts

Public ContactWang Xin

wangxin77213@yahoo.com.cn+86 0 13208188462

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026